Patient considerations in the management of toe onychomycosis – role of efinaconazole

References

• GuptaAKJainHCLyndeCWMacdonaldPCooperEASummerbellRCPrevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter canadian survey of 15,000 patientsJ Am Acad Dermatol2000432 Pt 124424810906646
   PubMed Web of Science ®Google Scholar
• ElewskiBEThe effect of toenail onychomycosis on patient quality of lifeInt J Dermatol199736107547569372349
   PubMed Web of Science ®Google Scholar
• LubeckDPPatrickDLMcNultyPFiferSKBirnbaumJQuality of life of persons with onychomycosisQual Life Res1993253413488136799
   PubMed Web of Science ®Google Scholar
• ScheinJRGauseDStierDMLubeckDPBatesMMFiskROnychomycosis. Baseline results of an observational studyJ Am Podiatr Med Assoc199787115125199397656
   PubMed Web of Science ®Google Scholar
• ScherRKOnychomycosis: a significant medical disorderJ Am Acad Dermatol1996353 Pt 2S2S58784302
   PubMed Web of Science ®Google Scholar
• MilobratovicDJankovicSVukicevicJMarinkovicJJankovicJRailicZQuality of life in patients with toenail onychomycosisMycoses201356554355123496237
   PubMed Web of Science ®Google Scholar
• RoujeauJCSigurgeirssonBKortingHCKerlHPaulCChronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control studyDermatology2004209430130715539893
   PubMed Web of Science ®Google Scholar
• BristowIRSpruceMCFungal foot infection, cellulitis and diabetes: a reviewDiabet Med200926554855119646196
   PubMed Web of Science ®Google Scholar
• MartyJPLambertJJackelAAdjadjLTreatment costs of three nail lacquers used in onychomycosisJ Dermatolog Treat2005165–629930716428149
   PubMed Web of Science ®Google Scholar
• Arenas-GuzmanRTostiAHayRHanekeENational Institue for Clinical ExcellencePharmacoeconomics – an aid to better decision-makingJ Eur Acad Dermatol Venereol200519Suppl 1343916120204
   PubMed Web of Science ®Google Scholar
• ElewskiBERichPTostiAOnchomycosis: an overviewJ Drugs Dermatol2013127s96s10323884508
   PubMedGoogle Scholar
• LitzCECavagnoloRZPolymerase chain reaction in the diagnosis of onychomycosis: a large, single-institute studyBr J Dermatol2010163351151420491764
   PubMed Web of Science ®Google Scholar
• GuptaAKSimpsonFCNew therapeutic options for onychomycosisExpert Opin Pharmacother20121381131114222533461
   PubMed Web of Science ®Google Scholar
• ElewskiBERichPPollakREfinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studiesJ Am Acad Dermatol201368460060823177180
   PubMed Web of Science ®Google Scholar
• LooDSOnychomycosis in the elderly: drug treatment optionsDrugs Aging200724429330217432924
   PubMed Web of Science ®Google Scholar
• FosterKWGhannoumMAElewskiBEEpidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002J Am Acad Dermatol200450574875215097959
   PubMed Web of Science ®Google Scholar
• GuptaAKDrummond-MainCCooperEABrintnellWPiracciniBMTostiASystematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatmentJ Am Acad Dermatol201266349450221820203
   PubMed Web of Science ®Google Scholar
• del PalacioACuetaraMSGarauMPereaSOnychomycosis: a prospective survey of prevalence and etiology in MadridInt J Dermatol200645787487616894673
   PubMed Web of Science ®Google Scholar
• ZaiasNRebellGChronic dermatophytosis syndrome due to Trichophyton rubrumInt J Dermatol19963596146178876284
   PubMed Web of Science ®Google Scholar
• ZaiasNOnychomycosisArch Dermatol197210522632744258535
   PubMedGoogle Scholar
• BaranRHayRJTostiAHanekeEA new classification of onychomycosisBr J Dermatol199813945675719892897
   PubMed Web of Science ®Google Scholar
• BaranRFaergemannJHayRJSuperficial white onychomycosis – a syndrome with different fungal causes and paths of infectionJ Am Acad Dermatol200757587988217610995
   PubMed Web of Science ®Google Scholar
• DompmartinDDompmartinADeluolAMGrosshansECoulaudJPOnychomycosis and AIDS. Clinical and laboratory findings in 62 patientsInt J Dermatol19902953373392141830
   PubMed Web of Science ®Google Scholar
• NoppakunNHeadESProximal white subungual onychomycosis in a patient with acquired immune deficiency syndromeInt J Dermatol19862595865872947870
   PubMed Web of Science ®Google Scholar
• GuptaAKLynchLEOnychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrenceCutis2004741 Suppl101515287395
   PubMed Web of Science ®Google Scholar
• BaranRSigurgeirssonBde BerkerDA multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvementBr J Dermatol2007157114915717553051
   PubMed Web of Science ®Google Scholar
• JenningsMBPollakRHarklessLBKianifardFTavakkolATreatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trialJ Am Podiatr Med Assoc200696646547317114599
   PubMed Web of Science ®Google Scholar
• LahfaMBulai-LivideanuCBaranREfficacy, safety and tolerability of an optimized avulsion technique with onyster(R) (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled studyDermatology2013226151223467055
   PubMed Web of Science ®Google Scholar
• TostiAOnychomycosis treatment and management2013 Available from: http://emedicine.medscape.com/article/1105828-treatmentAccessed December 21, 2014
   Google Scholar
• GuptaAKPharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysisPharmacoeconomics199813224325610178650
   PubMed Web of Science ®Google Scholar
• ChangCHYoung-XuYKurthTOravJEChanAKThe safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysisAm J Med2007120979179817765049
   PubMed Web of Science ®Google Scholar
• HavuVHeikkilaHKuokkanenKA double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosisBr J Dermatol200014219710210651701
   PubMed Web of Science ®Google Scholar
• SaloHPekurinenMCost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosisPharmacoeconomics200220531932411994041
   PubMed Web of Science ®Google Scholar
• de SaDCLamasAPTostiAOral therapy for onychomycosis: an evidence-based reviewAm J Clin Dermatol2014151173624352873
   PubMed Web of Science ®Google Scholar
• EvansEGSigurgeirssonBDouble blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study GroupBMJ199931871901031103510205099
   PubMed Web of Science ®Google Scholar
• SigurgeirssonBBillsteinSRantanenTL.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs Itraconazole in OnychomycosisBr J Dermatol1999141Suppl 5651410730908
   PubMed Web of Science ®Google Scholar
• DrakeLBabelDStewartDMOnce-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernailJ Am Acad Dermatol1998386 Pt 2S87S949631990
   PubMed Web of Science ®Google Scholar
• GuptaAKLambertJPharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USAInt J Dermatol199938Suppl 2536410515529
   PubMed Web of Science ®Google Scholar
• GuptaAKFleckmanPBaranRCiclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosisJ Am Acad Dermatol2000434 SupplS70S8011051136
   PubMed Web of Science ®Google Scholar
• WarshawEMEvaluating costs for onychomycosis treatments: a practitioner’s perspectiveJ Am Podiatr Med Assoc2006961385216415282
   PubMed Web of Science ®Google Scholar
• ElewskiBEOnychomycosis. Treatment, quality of life, and economic issuesAm J Clin Dermatol200011192611702301
   PubMedGoogle Scholar
• ElewskiBEOnychomycosis: pathogenesis, diagnosis, and managementClin Microbiol Rev19981134154299665975
   PubMed Web of Science ®Google Scholar
• GuptaAKRyderJESkinnerARTreatment of onychomycosis: pros and cons of antifungal agentsJ Cutan Med Surg200481253015688097
   PubMed Web of Science ®Google Scholar
• NoltingSKSanchez CarazoSDe BoulleKLambertJROral treatment schedules for onychomycosis: a study of patient preferenceInt J Dermatol19983764544569646137
   PubMed Web of Science ®Google Scholar
• HuYYangLJWeiLStudy on the compliance and safety of the oral antifungal agents for the treatment of onychomycosisZhonghua Liu Xing Bing Xue Za Zhi20052612988991 Chinese16676597
   PubMedGoogle Scholar
• WangJLChangCHYoung-XuYChanKASystematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infectionAntimicrob Agents Chemother20105462409241920308378
   PubMed Web of Science ®Google Scholar
• GuptaAKRyderJEJohnsonAMCumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosisBr J Dermatol2004150353754415030339
   PubMed Web of Science ®Google Scholar
• GuptaAKJosephWSCiclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United StatesJ Am Podiatr Med Assoc2000901049550111107710
   PubMed Web of Science ®Google Scholar
• TschenEHBuckoADOizumiNKawabataHOlinJTPillaiREfinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind studyJ Drugs Dermatol201312218619223377392
   PubMed Web of Science ®Google Scholar
• GuptaAKElewskiBESugarmanJLThe efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trialsJ Drugs Dermatol201413781582025007364
   PubMed Web of Science ®Google Scholar
• SugiuraKSugimotoNHosakaSThe low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatmentAntimicrob Agents Chemother20145873837384224752277
   PubMed Web of Science ®Google Scholar
• JarrattMSiuWJYamakawaEKoderaNPillaiRSmithKSafety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosisJ Drugs Dermatol20131291010101624002148
   PubMed Web of Science ®Google Scholar
• ZeichnerJAStein GoldLKorotzerAPenetration of ((14)C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail polishJ Clin Aesthet Dermatol201479343625276275
   PubMedGoogle Scholar
• TostiAElewskiBETreatment of onychomycosis with efinaconazole 10% topical solution and quality of lifeJ Clin Aesthet Dermatol2014711253025489379
   PubMedGoogle Scholar